TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7658052

Group type: EXPERIMENTAL
Intervention: ganciclovir
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: foscarnet
Number of subjects: 48

Group type: COMPARATOR
Intervention: maintenance therapy
Number of subjects: 48
Study: 2732449

Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha (rIFN alpha)‐2A, administered intramuscularly in doses ranging from 1.5 MU to 20 MU/m2 of body surface, two or three times weekly during 4‐6 months.
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha (rIFN alpha)‐2A
Number of subjects: 58
Study: 1184491

Group type: EXPERIMENTAL
Intervention: Response-cost plus reinforcement
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Response-cost only
Number of subjects: 15

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 15
Study: 28818850

Group type: EXPERIMENTAL
Intervention: SIDCER ICF
Number of subjects: 234

Group type: COMPARATOR
Intervention: Conventional ICF
Number of subjects: 234
Study: 27777439

Group type: EXPERIMENTAL
Intervention: EUS Sonopsy CY®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional needle
Number of subjects: 0
Study: 24894546

Group type: EXPERIMENTAL
Intervention: Biofinity Toric
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Proclear Toric
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acuvue Advance for Astigmatism
Number of subjects: 20

Group type: COMPARATOR
Intervention: Air Optix for Astigmatism
Number of subjects: 20

Group type: COMPARATOR
Intervention: PureVision Toric
Number of subjects: 20
Study: 22298121

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Riluzole (100-200 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 20227721

Group type: EXPERIMENTAL
Intervention: DHA/ARA-supplemented formula
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study: 18983318

Group type: EXPERIMENTAL
Intervention: Immediate restoration of single implants placed at the time of tooth extraction (test group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Immediate restoration of single implants placed 8 weeks after tooth extraction (control group)
Number of subjects: 16
Study: 16098300

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors during TAXUS stent implantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stent without GP IIb/IIIa inhibitors
Number of subjects: 0
Study: 14533561

Group type: EXPERIMENTAL
Intervention: Calcium supplementation or optimal dietary calcium intake
Number of subjects: 0
Study: 11104295

Group type: EXPERIMENTAL
Intervention: sustained‐release nifedipine
Number of subjects: 158

Group type: COMPARATOR
Intervention: pill placebo
Number of subjects: 158

Group type: COMPARATOR
Intervention: electromyography
Number of subjects: 158

Group type: COMPARATOR
Intervention: temperature biofeedback
Number of subjects: 158
Study: 8934156

Group type: EXPERIMENTAL
Intervention: Urea-membrane test
Number of subjects: 99

Group type: COMPARATOR
Intervention: Urea-gel method
Number of subjects: 99
Study: 1455381

Group type: EXPERIMENTAL
Intervention: tactivin
Number of subjects: 31

Group type: COMPARATOR
Intervention: conventional therapy
Number of subjects: 31
Study: 6384289

Group type: EXPERIMENTAL
Intervention: 5% topical minoxidil for 12 months
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1% topical minoxidil for 12 months
Number of subjects: 15
Study: 31129108

Group type: EXPERIMENTAL
Intervention: Subjective sleep parameters (total PSQI score)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Subjective sleep parameters (PSQI-sleep medication)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Subjective sleep parameters (PSQI-subjective sleep quality, PSQI-sleep latency, PSQI-sleep duration, PSQI-daytime dysfunction)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: PSQI-daytime dysfunction
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: PSQI-subjective sleep quality
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Global PSQI subjective sleep parameters
Number of subjects: 72
Study: 29378045

Group type: EXPERIMENTAL
Intervention: Maternal milk vitamin B-12 concentration
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Infant serum vitamin B-12 concentration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Maternal milk vitamin B-12 concentrations
Number of subjects: 100
Study: 26818974

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID or 10 mg BID
Number of subjects: 486
Study: 24742124

Group type: EXPERIMENTAL
Intervention: Metformin (M) 2 g/d
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metformin + Oral Contraceptive Pills (M+OCP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral Contraceptive Pills (OCP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metformin (M)
Number of subjects: 90
Study: 22883485

Group type: EXPERIMENTAL
Intervention: cART containing Tenofovir and a non-nucleoside reverse-transcriptase-inhibitor (TFV/NNRTI)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: cART containing Tenofovir and a protease-inhibitor (TFV/PI)
Number of subjects: 317

Group type: COMPARATOR
Intervention: cART without Tenofovir
Number of subjects: 317

Group type: COMPARATOR
Intervention: No cART
Number of subjects: 317
Study: 19840829

Group type: EXPERIMENTAL
Intervention: Hybrid resin composite (Clearfil AP‐X; AP)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Flowable resin composite (Clearfil Flow FX; FX)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both AP and FX
Number of subjects: 22
Study: 17894540

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Distilled cold water
Number of subjects: 34

Group type: COMPARATOR
Intervention: BAL fluid analysis
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 34
Study: 15668765

Group type: EXPERIMENTAL
Intervention: 5 cmH(2)O PEEP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 cmH(2)O PEEP
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (non-recruiters)
Number of subjects: 12
Study: 11744653

Group type: EXPERIMENTAL
Intervention: Sublingual cyclodextrin androstenediol (Sl Diol) 20 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 8
Study: 10512399

Group type: EXPERIMENTAL
Intervention: Hydrolyzed cow's milk protein formula
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard preterm infant formula
Number of subjects: 15
Study: 8547937

Group type: EXPERIMENTAL
Intervention: Feeding 2 (69 g CHO/400 ml)
Number of subjects: 6
Study: 1714761

Group type: EXPERIMENTAL
Intervention: Aprotinin (10,000 international units)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (1 ml)
Number of subjects: 0
Study: 6412271

Group type: EXPERIMENTAL
Intervention: Sulpiride morning only dose
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sulpiride daily total dose in two equal fractions at 8 a.m. and 4 p.m.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31276747

Group type: EXPERIMENTAL
Intervention: Resin sealants
Number of subjects: 41

Group type: COMPARATOR
Intervention: Glass ionomer sealants
Number of subjects: 41
Study: 29061504

Group type: EXPERIMENTAL
Intervention: Irinotecan plus S‐1 (IRI‐S)
Number of subjects: 105

Group type: COMPARATOR
Intervention: S‐1 therapy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: IRI‐S
Number of subjects: 105

Group type: COMPARATOR
Intervention: S‐1
Number of subjects: 105
Study: 27669109

Group type: EXPERIMENTAL
Intervention: Long pulsed Nd:YAG laser 532 nm
Number of subjects: 19

Group type: COMPARATOR
Intervention: Long pulsed Nd:YAG laser 1,064 nm
Number of subjects: 19
Study: 23235716

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET) for 12 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (inactive)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 21
Study: 21562067

Group type: EXPERIMENTAL
Intervention: saxagliptin 2.5 mg + glyburide 7.5 mg
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg + glyburide 7.5 mg
Number of subjects: 768

Group type: COMPARATOR
Intervention: up-titrated glyburide
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: saxagliptin 2.5 mg
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg
Number of subjects: 768
Study: 19595557

Group type: EXPERIMENTAL
Intervention: Intervention group (8 healthy-eating classes, 10 physical-activity classes, 6 telephone-counseling sessions over 9 months)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 450
Study: 16549457

Group type: EXPERIMENTAL
Intervention: L-[1-(13C)]leucine at 65 mg/(kg.d)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: L-[1-(13C)]leucine at 45 mg/(kg.d)
Number of subjects: 7

Group type: COMPARATOR
Intervention: L-[1-(13C)]lysine (control)
Number of subjects: 7
Study: 12775372

Group type: EXPERIMENTAL
Intervention: Canned rice (CR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canned rice meal with pork sausage (CRM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Canned rice (CR) and canned rice meal with pork sausage (CRM)
Number of subjects: 0
Study: 10681363

Group type: EXPERIMENTAL
Intervention: Delavirdine (DLV) monotherapy
Number of subjects: 30
Study: 9196609

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (dF) 15 mg twice daily for 7 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Naloxone (125 micrograms/kg i.v.)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Corticotropin releasing hormone (CRH) (1 microgram/kg i.v.)
Number of subjects: 16
Study: 8453437

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg, three times a day for six weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cisapride (continued for another six weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (continued for another six weeks)
Number of subjects: 12
Study: 3743143

Group type: EXPERIMENTAL
Intervention: Intranasal occlusion with petrolatum gauze
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nose open (control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intranasal occlusion
Number of subjects: 8
Study: 29603242

Group type: EXPERIMENTAL
Intervention: Peer-mentoring program
Number of subjects: 47
Study: 26547424

Group type: EXPERIMENTAL
Intervention: S‐1 plus paclitaxel (daily oral S‐1 at 80 mg/m² for 2 weeks plus paclitaxel at 50 mg/m² on days 1 and 8, every 3 weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Paclitaxel (weekly administration at 80 mg/m² three times every 4 weeks)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: S‐1 plus paclitaxel
Number of subjects: 78

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 78
Study: 24293120

Group type: EXPERIMENTAL
Intervention: Telerehabilitation intervention (activity coach with 3D-accelerometer and smartphone) for 4 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Telerehabilitation intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 34
Study: 22876444

Group type: EXPERIMENTAL
Intervention: Chinese yam-epimedium mixture
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 20464817

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no IMT)
Number of subjects: 14
Study: 18387656

Group type: EXPERIMENTAL
Intervention: NT‐proBNP (Q4)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Other biomarkers (hsCRP, MMP‐9, PAPP‐A, MPO, sCD40L, FM)
Number of subjects: 298
Study: 17925000

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Number of subjects: 467

Group type: COMPARATOR
Intervention: Placebo or no treatment (controls)
Number of subjects: 467
Study: 15717139

Group type: EXPERIMENTAL
Intervention: Cisapride 0.3 mg/kg daily
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cisapride 0.6 mg/kg daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no Cisapride)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cisapride treatment
Number of subjects: 46
Study: 11598607

Group type: EXPERIMENTAL
Intervention: Soy formula with added soy fiber
Number of subjects: 45

Group type: COMPARATOR
Intervention: Regular soy formula (without added fiber)
Number of subjects: 45
Study: 9393335

Group type: COMPARATOR
Intervention: Whole-cell DTP vaccine (n = 20,720)
Number of subjects: 82892

Group type: EXPERIMENTAL
Intervention: Five-component acellular DTP vaccine (n = 20,747)
Number of subjects: 82892

Group type: EXPERIMENTAL
Intervention: Three-component acellular DTP vaccine (n = 20,728)
Number of subjects: 82892

Group type: EXPERIMENTAL
Intervention: Two-component acellular DTP vaccine (n = 20,697)
Number of subjects: 82892
Study: 7514842

Group type: EXPERIMENTAL
Intervention: PPSA (polyclonal antibodies)
Number of subjects: 421

Group type: COMPARATOR
Intervention: MPSA (monoclonal antibodies)
Number of subjects: 421
Study: 3605184

Group type: EXPERIMENTAL
Intervention: 1 mg per day of warfarin for 18 months
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 10651597

Group type: EXPERIMENTAL
Intervention: Manual therapy and standardized knee exercise program
Number of subjects: 83

Group type: COMPARATOR
Intervention: Subtherapeutic ultrasound to the knee
Number of subjects: 83
Study: 30472808

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Nonusers of proton pump inhibitors
Number of subjects: 1198
Study: 29486493

Group type: EXPERIMENTAL
Intervention: Bedside Paediatric Early Warning System (BedsidePEWS)
Number of subjects: 144539

Group type: COMPARATOR
Intervention: Usual care (no severity of illness score)
Number of subjects: 144539
Study: 26662809

Group type: EXPERIMENTAL
Intervention: Multi-dimensional Treatment Foster Care (MTFC)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care (TAU)
Number of subjects: 171
Study: 24436354

Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (70 mL of concentrated beetroot juice containing a minimum of 0.3 g of nitrate)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (70 mL of placebo)
Number of subjects: 16
Study: 22810982

Group type: COMPARATOR
Intervention: MNP group (maize porridge with multi-micronutrient powder containing 2.5 mg iron as NaFeEDTA; 6.6 mg iron/meal)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Amaranth group (unrefined maize 30% and amaranth grain 70% porridge; 23 mg iron/meal)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control group (unrefined maize porridge; 4.1 mg iron/meal)
Number of subjects: 279
Study: 20599002

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day and Ezetimibe 10 mg/day
Number of subjects: 100
Study: 16920077

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1.5 g/d; .84 g/d eicosapentaenoic acid, .7 g/d docosahexaenoic acid)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 16247531

Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol (10 mg/4 mL) via jet nebulizer for 30 min on ZEEPe
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol (10 mg/4 mL) via jet nebulizer for 30 min on PEEPe
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of PEEPe and fenoterol
Number of subjects: 10
Study: 12453332

Group type: EXPERIMENTAL
Intervention: Capecitabine (1250 mg/m2 twice daily for 14 days, every 3 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0
Study: 10433619

Group type: EXPERIMENTAL
Intervention: SPF 10 sunscreen (n = 44)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: SPF 30 sunscreen (n = 42)
Number of subjects: 87
Study: 7887554

Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole (one double‐strength tablet daily, five times a week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole
Number of subjects: 60
Study: 2487803

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg) + Captopril (50 mg)
Number of subjects: 0
Study: 775145

Group type: EXPERIMENTAL
Intervention: ampicillin‐cloxacillin (Rectocillin) 1 g/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: ampicillin (AB‐PC) 1 g/day
Number of subjects: 0
Study: 31996367

Group type: EXPERIMENTAL
Intervention: ETN+MTX
Number of subjects: 120

Group type: COMPARATOR
Intervention: MTX-TT
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ETN administered first line
Number of subjects: 120
Study: 31094901

Group type: EXPERIMENTAL
Intervention: Intravenous vortioxetine 17 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 55
Study: 28067119

Group type: EXPERIMENTAL
Intervention: ATV 400 mg daily (switch)
Number of subjects: 50

Group type: COMPARATOR
Intervention: ATV/r 300/100 mg daily (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 50
Study: 25659357

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (only primary closure)
Number of subjects: 31
Study: 24169735

Group type: EXPERIMENTAL
Intervention: Atrial pacing (%AP)
Number of subjects: 396
Study: 22526538

Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19237720

Group type: EXPERIMENTAL
Intervention: Patient mailings containing an educational pamphlet, fecal occult blood test kit, and instructions for scheduling screening.
Number of subjects: 21860

Group type: COMPARATOR
Intervention: Electronic reminders to physicians during office visits.
Number of subjects: 21860

Group type: EXPERIMENTAL
Intervention: Electronic reminders to physicians for patients with 3 or more primary care visits.
Number of subjects: 21860

Group type: EXPERIMENTAL
Intervention: Patient mailings and physician reminders for detection of adenomas.
Number of subjects: 21860
Study: 17692718

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.5 mg QD
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 2.0 mg BID
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 1.0 mg BID
Number of subjects: 758

Group type: COMPARATOR
Intervention: Budesonide DPI 400 microg BID (active reference arm)
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: All BIS dosages
Number of subjects: 758
Study: 15334776

Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 2561

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 2561

Group type: EXPERIMENTAL
Intervention: Past use of glass syringes
Number of subjects: 2561

Group type: EXPERIMENTAL
Intervention: Combination of risk factors
Number of subjects: 2561

Group type: EXPERIMENTAL
Intervention: Subjects younger than 46 years of age
Number of subjects: 2561
Study: 15476998

Group type: EXPERIMENTAL
Intervention: Structured education
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard nursing care
Number of subjects: 30
Study: 11704494

Group type: EXPERIMENTAL
Intervention: Active low-intensity pulsed ultrasound (US) at 30 mW/cm² for 20 min/day, 5 days/week, over 6 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Inactive ultrasound (US) treatment
Number of subjects: 15
Study: 9140518

Group type: EXPERIMENTAL
Intervention: CR challenge preceded by D.p. challenge (CR2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CR challenge preceded by sham challenge (CR1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CR2
Number of subjects: 12
Study: 8433424

Group type: EXPERIMENTAL
Intervention: Ancrod
Number of subjects: 28

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 28
Study: 3660329

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids supplementation (2.880 g/day for 12 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study: 29614582

Group type: EXPERIMENTAL
Intervention: Bifidobacterium tetragenous viable bacteria tablets
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 28801420

Group type: EXPERIMENTAL
Intervention: Multiple-monopolar anodal transcranial direct current stimulation during upper limb motor training involving virtual reality
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation during upper limb motor training involving virtual reality
Number of subjects: 0
Study: 26208402

Group type: EXPERIMENTAL
Intervention: Childhood victimization (physical assault, sexual abuse)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Childhood victimization (sleep problems)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Health risk behaviors and mental health problems
Number of subjects: 2500
Study: 24010901

Group type: EXPERIMENTAL
Intervention: Mobi-C cervical artificial disc (TDR)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 330
Study: 21621252

Group type: EXPERIMENTAL
Intervention: Escalating doses of omega-3 PUFA (1 to 8 g daily over 24 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aspirin and clopidogrel
Number of subjects: 30
Study: 18502301

Group type: EXPERIMENTAL
Intervention: Enhanced care including additional time with practice nurse and support from a link worker and diabetes-specialist nurse
Number of subjects: 1486

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1486
Study: 16789351

Group type: EXPERIMENTAL
Intervention: Performance feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 12952151

Group type: EXPERIMENTAL
Intervention: Balance exercise group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Gait exercise group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 10980764

Group type: EXPERIMENTAL
Intervention: Foscarnet sodium and ganciclovir sodium as therapy for newly diagnosed CMV retinitis
Number of subjects: 0
Study: 9004108

Group type: EXPERIMENTAL
Intervention: Enalapril/Diltiazem ER
Number of subjects: 62